Met Non Small Cell Cancer Registry (MOMENT)
Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)
1 other identifier
observational
700
14 countries
64
Brief Summary
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2022
Longer than P75 for all trials
64 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 11, 2022
CompletedFirst Posted
Study publicly available on registry
May 17, 2022
CompletedStudy Start
First participant enrolled
October 4, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 28, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
April 28, 2028
April 15, 2026
April 1, 2026
5.6 years
May 11, 2022
April 14, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (5)
Best Overall Response (BOR)
Through study completion, up to approximately 4.9 years
Tumor Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1
Up to approximately 4.9 years
Overall Survival (OS)
Through study completion, up to approximately 4.9 years
Number of Participants with Adverse Events (AEs)
Up to approximately 4.9 years
Number of Participants with Adverse Reactions (ARs)
Up to approximately 4.9 years
Study Arms (1)
Advanced Non-small Cell Lung Cancer with METex14 skipping alterations
Participants diagnosed with advanced NSCLC and who receive available therapies in routine clinical practice setting will be part of this registry. Data will be collected routinely from the point of enrollment of a participants into the registry until death, loss to follow-up (drop-out), subsequent enrollment into a clinical trial, or end of data collection period for the registry.
Eligibility Criteria
Participants with advanced stage (stages IIIB-IV) NSCLC and confirmed METex14 skipping alterations who are initiating or already treated with a systemic therapy will be included.
You may qualify if:
- Participants who signed ICF
- Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)
- Participants who are starting or are already being treated with systemic therapy
You may not qualify if:
- Participants who are enrolled in a clinical trial
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (64)
Holy Cross Health
Fort Lauderdale, Florida, 33308-4603, United States
The Ohio State University Wexner Medical Center
Columbus, Ohio, 43221, United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37212, United States
Klinikum Klagenfurt Am Woerthersee
Klagenfurt, Austria
Klinik Floridsdorf
Vienna, Austria
AZ Delta
Roeselare, Belgium
AZ Nikolaas
Sint-Niklaas, Belgium
Ottawa Hospital General Campus
Ottawa, Canada
Princess Margaret Cancer Centre
Toronto, Canada
FN Olomouc
Olomouc, Czechia
University Hospital Na Bulovce
Prague, Czechia
Centre Hospitalier de Cholet
Cholet, France
CHRU Lille
Lille, France
Hôpital du Scorff
Lorient, France
Centre Leon Berard
Lyon, France
Hospital Tenon & University Paris 6
Paris, France
Institut Curie - Centre de Lutte Contre le Cancer (CLCC)
Paris, France
CHU de Pontchaillou
Rennes, 35 033, France
CHU de Toulouse Hopital Larrey
Toulouse, France
Klinikum Chemnitz GmbH
Chemnitz, Germany
KKH Grosshansdorf GmbH
Großhansdorf, Germany
Thoraxklinik-Heidelberg gGmbH
Heidelberg, Germany
Klinik Löwenstein GmbH
Löwenstein, Germany
Haemek Medical Center
Afula, Israel
Bnei-Zion Medical Center
Haifa, Israel
Carmel Medical Center
Haifa, Israel
Rambam Medical Center - PPDS
Haifa, Israel
Shaare Zedek Medical Center
Jerusalem, Israel
Rabin Medical Center Oncology Beilinson Campus
Petah Tikva, Israel
Chaim Sheba Medical Center
Ramat Gan, Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Istituto Europeo di Oncologia
Milan, Italy
Istituto Nazionale Dei Tumori
Milan, Italy
Azienda Ospedaliera Dei Colli - Ospedale Monaldi
Naples, 80131, Italy
AOU dell'Università degli Studi della Campania Luigi Vanvitelli
Naples, Italy
I.F.O. Istituto Nazionale Tumori Regina Elena IRCCS
Rome, Italy
Azienda Sanitaria Ospedaliera S Luigi Gonzaga
Torino, Italy
Ospedale di Circolo
Varese, Italy
VU Medisch Centrum
Amsterdam, Netherlands
Universitair Medisch Centrum Groningen - Department of Medical Oncology
Groningen, Netherlands
Leiden University Medical Center
Leiden, Netherlands
Centro Hospitalar de Lisboa Norte, EPE - Hospital de Santa Maria
Lisbon, Portugal
Centro Hospitalar do Porto E.P.E. Hospital de Santo António
Porto, Portugal
Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe - PPDS
Porto Covo, Portugal
Clinica Tres Torres
Barcelona, Spain
Institut Universitari Dexeus-Quiron - Servei d oncologia medica - Institut Oncologic Dr. Rosell
Barcelona, Spain
Complejo Hospitalario Universitario Insular-Materno Infantil
Las Palmas de Gran Canaria, Spain
Centro Integral Oncologico Clara Campa
Madrid, Spain
Centro Oncologico MD Anderson
Madrid, Spain
Hospital Regional Universitario de Malaga - Hospital General
Málaga, Spain
Hospidal Universitario Ntra. Sra. De Valme
Seville, Spain
Hospital Universitario Virgen Macarena
Seville, Spain
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, Spain
Universitetssjukhuset i Linköping
Linköping, Sweden
Huddersfield Royal Infirmary
Huddersfield, West Yorkshire, HD3 3EA, United Kingdom
Bedford General Hospital
Bedford, United Kingdom
Birmingham Heartlands Hospital
Birmingham, United Kingdom
Royal Bournemouth Hospital
Bournemouth, United Kingdom
The Royal Marsden Hospital
Chelsea, United Kingdom
Northwick Park Hospital
Harrow, United Kingdom
Clatterbridge Cancer Centre - Liverpool
Liverpool, United Kingdom
Guy's Cancer Centre
London, SE1 9RT, United Kingdom
Charing Cross Hospital
London, United Kingdom
Preston Hospital
Preston, United Kingdom
Related Publications (1)
Thomas M, Christopoulos P, Iams WT, Mazieres J, Cortot AB, Peled N, Minuti G, Smit EF, Audhuy F, Berghoff K, Eggleton SP, Fries F, Hildenbrand M, Liu P, Mahmoudpour SH, Menzel C, Oksen D. MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy. J Comp Eff Res. 2025 Feb;14(2):e240127. doi: 10.57264/cer-2024-0127. Epub 2025 Jan 21.
PMID: 39836056DERIVED
Related Links
MeSH Terms
Conditions
Study Officials
- STUDY DIRECTOR
Medical Responsible
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 11, 2022
First Posted
May 17, 2022
Study Start
October 4, 2022
Primary Completion (Estimated)
April 28, 2028
Study Completion (Estimated)
April 28, 2028
Last Updated
April 15, 2026
Record last verified: 2026-04